Current status of immunization against anthrax: Old vaccines may be here to stay for a while

Current Opinion in Infectious Diseases

Volumn 13, Issue 2, 2000, Pages 113-120

  Turnbull, Peter C B ^a,b  

^a Arjemptur Technology Ltd   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; SQUALENE; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ANTHRAX; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; HUMAN; IMMUNIZATION; MACROPHAGE; MILITARY MEDICINE; NONHUMAN; REVIEW; VACCINATION; VACCINE PRODUCTION;

EID: 0034003059     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200004000-00004     Document Type: Review

References (104)

1. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine 1991; 9:533-539.
2. Henderson DA. The looming threat of bioterrorism. Science 1999; 283:1279-1282.
3. Chin J. Pentagon orders anthrax vaccination for Gulf troops. ProMED-mail post, 4 March 1998.
4. MacKenzie D. Naked into battle. Preparations for war in the Gulf have highlighted a major hole in the West's defences. New Scientist 1998; 28 February, p. 4.
5. Nass M. Biological warfare [Letter]. Lancet 1998; 352:491-492.
6. GAO. Medical readiness. Safety and efficacy of the anthrax vaccine. 1999; GAO/T-NSIAD-99-148.
7. Fox JL. Rotavirus, other vaccines encounter bumpy road. ASM News 1999; 65:671-672.
8. Nass M. Anthrax vaccine. Model of a response to the biologic warfare threat. Infect Dis Clin North Am 1999; 13:187-208. Dr Nass, although not having specifically worked on anthrax or its causative agent, has played a key role in some of the more hotly debated issues surrounding the subject, including a strong suggestion that the massive outbreak in humans in Zimbabwe in 1979-1980 was an act of biological warfare (Physicians for Social Responsibility Quarterly 1992; 2:198-209).
9. Anonymous. Defense Department to start immunizing troops against anthrax. News Release, Office of Assistant Secretary of Defense (Public Affairs), Washington DC 20301, 15 December 1997.
10. Robertson GA. Total force anthrax vaccination decision announced. ProMED-mail post, 22 May 1998.
11. Cairney R. Antivaccine advocates line up to support airman. Can Med Assoc J 1999; 160:883.
12. Morris K. US military face punishment for refusing anthrax vaccine. Lancet 1999; 353:130.
13. Gilligan A, Almond P. British troops 'mutiny' over Gulf anthrax jab. ProMED-mail post, 8 June 1998.
14. Pasteur L. De l'atténuation des virus et de leur retour à la virulence. CR Acad Sci Agric Bulg 1881; 92:429-435.
15. Sterne M. The effects of different carbon dioxide concentrations on the growth of virulent anthrax strains. Pathogenicity and immunity tests on guinea-pigs and sheep with anthrax variants derived from virulent strains. Onderstepoort J Vet Sci An Ind 1937; 9:49-67.
16. Wright GG, Hedberg MA, Slein JB. Studies on immunity in anthrax. III. Elaboration of protective antigen in a chemically defined, non-protein medium. J Immunol 1954; 72:263-269.
17. Wright GG, Green TW, Kanode RG. Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen. J Immunol 1954; 73:387-391.
18. Wright GG, Puziss M. Elaboration of protective antigen of Bacillus anthracis under anaerobic conditions. Nature 1957; 179:916-917.
19. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Publ Hlth 1962; 52:632-645.
20. Wright GG, Puziss M, Neely WB. Studies on immunity in anthrax. IX. Effect of variations in culture conditions on elaboration of protective antigen by strains of Bacillus anthracis. J Bacteriol 1962; 83:515-522.
21. Puziss M, Manning LC, Lynch JW, Barclay E, Abelow I, Wright GG. Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. Appl Microbiol 1963: 11:330-334.
22. Puziss M, Wright GG. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man. J Bacteriol 1963; 85:230-236.
23. United States Patent Office. Anaerobic process for production of a gel- adsorbed anthrax immunizing antigen. Patent 3,208,909, 28 September 1965.
24. Auerbach S, Wright GG. Studies on immunity in anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis. J Immunol 1955; 75:129-133.
25. Federal Register. Biological products, bacterial vaccines and toxoids; implementation of efficacy review; proposed rule. Food and Drug Administration, Department of Health and Human Services, 21 CFR 610, Part II. Washington DC, 1985.
26. American Academy of Pediatrics. Anthrax. In: Report of the Committee on Infectious Diseases, 24th ed. Peter G (editor) Red Book. Elk Grove Village, IL: American Academy of Pediatrics, 1997. pp. 135-137.
27. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, et al. (Working Group on Civilian Biodefense). Anthrax as a biological weapon: medical and public health management. JAMA 1999; 281:1735-1745.
28. Belton FC, Strange RE. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br J Exp Pathol 1954; 35:144-152.
29. Anonymous. Vaccine against anthrax. BMJ 1965; ii:717-718.
30. Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994; 12:727-730.
31. Dong SL. Progress in the control and research of anthrax in China. Salisbury Med Bull 1990; 68 (Special suppl.): 104-105.
32. Turnbull PCB, Böhm R, Cosivi O, Doganay M, Hugh-Jones ME, Joshi DD, et al. Guidelines for the surveillance and control of anthrax in humans and animals. WHO/EMC/ZDI./98.6. 1998.
33. Ivins BE, Fellows PF, Nelson GO. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 1994; 12:872-874.
34. Ibrahim KH, Brown G, Wright DH, Rotschafer JC. Bacillus anthracis: medical issues of biologic warfare. Pharmacotherapy 1999; 19:690-701.
35. Kaufmann A. Anthrax vaccine safety and efficacy. ProMED-mail post. 15 April 1998.
36. Demicheli V, Rivetti D, Deeks JJ, Jefferson T, Pratt M. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine 1998; 16:880-884.
37. Darlow HM, Pride NB. Serological diagnosis of anthrax. Lancet 1969; ii:430.
38. CDSC. Anthrax surveillance 1961-80. PHLS Communicable Dis Report 1981; 81/46.
39. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202-1208.
40. Ivins BE, Welkos SL. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 1988; 4:12-19.
41. Ivins BE, Fellows PF, Pitt MLM, Estep JE, Welkos SL, Worsham PL, Friedlander AM. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med J 1996; 87 (Special suppl.):125-126.
42. Ivins BE, Pitt MLM, Fellows PF, Farchaus JW, Benner GE, Waag DM, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998; 16:1141-1148. The tests featured in this paper are the beginnings of what will be minimum requirements for regulatory acceptance of a future vaccine in which clinical trials will have to be replaced by surrogate markers of protection; a concept not yet fully accepted by regulatory authorities.
43. Pitt MLM, Little S, Ivins BE, Fellows P, Boles J, Barth J, et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 1999; 87:304.
44. Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158:429-434.
45. Ness AR, Harvey I, Gunnell D, Smith GD. All troops sent to Gulf should be randomised to receive anthrax vaccination or placebo [Letter]. BMJ 1998; 316:1322.
46. Nass M. Concerns regarding announced anthrax vaccinations: lack of demonstrated safety and efficacy. ProMED-mail post, 2 January 1998.
47. Morris K. US anthrax-vaccine producer saved for now. Lancet 1998; 351:657.
48. Dasey C. Anthrax vaccine safety and efficacy - USA. ProMED-mail post, 26 March 1998.
49. Cimons M. Pentagon readies massive anthrax vaccination program. ASM News 1996; 62:622-623.
50. Johnson JA. Medical officer of Marine Corps explains anthrax vaccination program. Marine Corps News, 13 January 1999.
51. Nass M. Anthrax vaccine safety and efficacy - USA. ProMED-mail post, 10 April 1998.
52. GAO. Gulf war illnesses. Improved monitoring of clinical progress and reexamination of research emphasis are needed. United States General Accounting Office, GAO/NSIAD-97-163, 1997.
53. Nass M. Anthrax vaccine and the prevention of biological warfare? ASA Newsletter 1998, 65:1, 23-25, 32. A clear statement of why vaccines are not the answer to the problems posed by potential biological aggression.
54. GAO. Gulf war illnesses. Questions about the presence of squalene antibodies in veterans can be resolved. United States General Accounting Office, GAO/NSIAD-99-5, 1999.
55. Matsumoto G. The Pentagon's toxic secret. Vanity Fair, May 1999, pp. 32-45.
56. Rook GAW, Zumia A. Gulf War syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet 1997; 349:1831-1833.
57. Blain P, Lightfoot N, Bannister B, Practicalities of warfare required service personnel to be vaccinated against anthrax [Letter]. BMJ 1998; 317:1077-1078.
58. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997; 65:5171-5175.
59. McBride BW, Mogg A, Telfer JL, Lever MS, Miller J, Turnbull PCB, Baillie L. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998; 16:810-817. A serious first attempt at identifying surrogate markers of protection.
60. Baillie LWJ, Fowler K, Turnbull PCB. Human immune responses to the UK human anthrax vaccine. J Appl Microbiol 1999; 87:306-308.
61. Watkins D. MHC of non-human primates. Curr Top Microbiol Immunol 1994; 188:145-159.
62. Hanna P. Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 1998; 225:13-55. An excellent up to date overview of today's understanding of the pathogenesis of anthrax.
63. Guidi-Rontani C, Weber-Levy M, Labruyère E, Mock M. Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 1999; 31:9-17.
64. Liddington R, Pannifer A, Hanna P, Leppla S, Collier RJ. Crystallographic studies of the anthrax lethal toxin. J Appl Microbiol 1999; 87:282.
65. Bhatnagar R, Ahuja N, Goila R, Batra S, Waheed SM, Gupta P. Activation of phospholipase C and protein kinase C is required for expression of anthrax lethal toxin cytotoxicity in J774A. 1 cells. Cell Signal 1999; 11:111-116.
66. Tang G, Leppla SH. Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect Immun 1999; 67:3055-3060.
67. 2 activation in anthrax lethal toxin-induced cytotoxicity. Cell Biol Toxicol 1999; 15:19-29.
68. Lindblad EP. Aluminium adjuvants. In: The theory and practical applications of adjuvants. Stewart-Tull DES (editor). Chichester, UK: John Wiley; 1995. pp. 21-36.
69. Farchaus JW, Ribot WJ, Jendrek S, Little SF. Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl Environ Microbiol 1998; 64:982-991.
70. Worsham PL, Sowers MR. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can J Microbiol 1999; 45:1-8.
71. •].
72. Miller J, McBride BW, Manchee RJ, Moore P, Baillie LWJ. Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Lett Appl Microbiol 1998; 26:56-60.
73. Baillie L, Moir A, Manchee R. The expression of the protective antigen of Bacillus anthracis and Bacillus subtilis. J Appl Microbiol 1998; 84:741-746. The British workers believe there are good reasons for using a species other than B. anthracis for the next-generation vaccine.
74. Baillie LWJ, Moore P, McBride BW. A heat-inducible Bacillus subtilis bacteriophage phi 105 expression system for the production of the protective antigen of Bacillus anthracis. FEMS Microbiol Lett 1998; 163:43-47.
75. •].
76. Singh Y, Ivins BE, Leppla SH. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect Immun 1998; 66:3447-3448.
77. Zegers ND, Kluter E, van der Stap H, van Dura E, van Dalen P, Shaw M, Baillie L. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J Appl Microbiol 1999; 87:309-314.
78. Gu M-L, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 1999; 17:340-344.
79. Williamson ED, Beedham RJ, Bennett AM, Perkins SD, Miller J, Baillie LWJ. Presentation of protective antigen to the mouse immune system: immune sequelae. J Appl Microbiol 1999; 87:315-317.
80. Wang XM, Wattiez R, Brassier F, Mock M, Falmagne P, Ruysschaert JM, Cabiaux V. Use of a photoactivatable lipid to probe the topology of PA63 of Bacillus anthracis in lipid membranes. Eur J Biochem 1998; 256:179-183. A serious start towards a DNA vaccine for anthrax.
81. Benson EL, Huynh PD, Finkelstein A, Collier RJ. Identification of residues lining the anthrax protective antigen channel. Biochemistry 1998; 37:3941-3948.
82. Ballard JD, Collier RJ, Starnbach MN. Anthrax toxin as a molecular tool for stimulation of cytotoxic T lymphocytes: disulfide-linked epitopes, multiple injections, and role of CD4+ cells. Infect Immun 1998; 66:4696-4699.
83. Doling AM, Ballard JD, Shen H, Krishna KM, Ahmed R, Collier RJ, Starnbach MN. Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Infect Immun 1999; 67:3290-3296.
84. Ballard JD, Doling AM, Beauregard K, Collier RJ, Starnbach MN. Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin. Infect Immun 1998; 66:615-619.
85. Varughese M, Chi A, Teixeira AV, Nicholls PJ, Keith JM, Leppla SH. Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol Med 1998; 4:87-95.
86. Leppla SH, Arora N, Varughese M. Anthrax toxin fusion proteins for intracellular delivery of macromolecules. J Appl Microbiol 1999; 87:284.
87. Price LB, Hugh-Jones M, Jackson PJ, Keim P. Genetic diversity in the protective antigen gene of Bacillus anthracis. J Bacteriol 1999; 181:2358-2362.
88. Pomerantsev AP, Staritsin NA, Mockov YV, Marinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 1997; 15:1846-1850.
89. Brassier F, Sirard J-C, Guidi-Rontani C, Duflot E, Mock M. Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect Immun 1999; 67:964-967.
90. Cirino NM, Sblattero D, Allen D, Peterson SR, Marks JD, Jackson PJ, et al. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun 1999; 67:2957-2963.
91. Varughese M, Teixeira AV, Liu S, Leppla SH. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun 1999; 67:1860-1865.
92. Wesche J, Elliott JL, Falnes P.Ø, Olsnes S, Collier RJ. Characterization of membrane translocation by anthrax protective antigen. Biochemistry 1998; 37:15737-15746.
93. Beauregard KE, Wimer-Mackin S, Collier RJ, Lencer WI. Anthrax toxin entry into polarized epithelial cells. Infect Immun 1999; 67:3026-3030.
94. Collier RJ. Mechanism of membrane translocation by anthrax toxin: insertion and pore formation by protective antigen. J Appl Microbiol 1999; 87:283.
95. Duesbery NS, Van de Woude GF. Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase. J Appl Microbiol 1999; 87:289-293.
96. Miller CJ, Elliott JL, Collier RJ. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 1999; 38:10432-10441.
97. Singh Y, Klimpel KR, Goel S, Swain PK, Leppla SH. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect Immun 1999; 67:1853-1859.
98. Mesnage S, Tosi-Couture E, Gounon P, Mock M, Fouet A. The capsule and S-layer: two independent and yet compatible macromolecular structures in Bacillus anthracis. J Bacteriol 1998; 180:52-58.
99. Mesnage S, Tosi-Couture E, Fouet A. Production and cell surface anchoring of functional fusions between the SLH motifs of the Bacillus anthracis S-layer proteins and the Bacillus subtilis levansucrase. Mol Microbiol 1999; 31:927-936.
100. Mesnage S, Tosi-Couture E, Mock M, Fouet A. The S-layer homology domain as a means for anchoring heterologous proteins on the cell surface of Bacillus anthracis. J Appl Microbiol 1999; 87:256-260.
101. Fouet A, Mesnage S, Tosi-Couture E, Gounon P, Mock M. Bacillus anthracis surface: capsule and S-layer. J Appl Microbiol 1999; 87:251-255.
102. ••]. This opens up possibilities for the rapid identification of other virulence factors and potential vaccine components.
103. Read T, Peterson S. Whole genome sequencing of Bacillus anthracis. Abstracts of the 2nd International Workshop on the Molecular Biology of Bacillus cereus, Bacillus anthracis and Bacillus thuringiensis. Taos, New Mexico, 11-13 August 1999. The B. anfhracis genome is an estimated 5 Mb; the sequence will be made available through the TIGR microbial database site (www.tigr.org/tdb/mdb/mdb.html).
104. Brossier F, Mock M, Sirard J-C. Antigen delivery by attenuated Bacillus anthracis: new prospects in veterinary vaccines. J Appl Microbiol 1999; 87:298-302.